Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (61-70 of 191) with videos related to

Pageof 20
Sort By:
Neurourology and Urodynamics|September 10, 2011
Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladderTara Frenkl, Radha Railkar, Neal Shore, et al.
Clinical Genitourinary Cancer|December 26, 2022
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate CancerNeal Shore, Begoña Mellado, Satish Shah, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 2, 2026
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United StatesNeal Shore, Benjamin Lowentritt, Charmi Patel, et al.
Urology|March 23, 2022
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate CancerBenjamin Lowentritt, Gordon Brown, Dominic Pilon, et al.
Advances in Therapy|August 26, 2022
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect ComparisonNeal Shore, Shan Jiang, Viviana Garcia-Horton, et al.
European Urology Oncology|May 1, 2025
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE TrialsChristopher J D Wallis, Sara Ekberg, Alicia K Morgans, et al.
European Urology|August 31, 2014
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trialFred Saad, Johann de Bono, Neal Shore, et al.
The Journal of Urology|May 10, 2024
Reply by AuthorsYair Lotan, Siamak Daneshmand, Neal Shore, et al.
Future Oncology (London, England)|March 13, 2020
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBCAshish M Kamat, Neal Shore, Noah Hahn, et al.
Practical Radiation Oncology|September 1, 2023
Barrigel Spacer Injection TechniqueGlen Gejerman, Martin M Goldstein, Michael Chao, et al.
Pageof 20

Showing results (61-70 of 191) with videos related to

Sort By:
Pageof 20
Neurourology and Urodynamics|September 10, 2011
Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladderTara Frenkl, Radha Railkar, Neal Shore, et al.
Clinical Genitourinary Cancer|December 26, 2022
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate CancerNeal Shore, Begoña Mellado, Satish Shah, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 2, 2026
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United StatesNeal Shore, Benjamin Lowentritt, Charmi Patel, et al.
Urology|March 23, 2022
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate CancerBenjamin Lowentritt, Gordon Brown, Dominic Pilon, et al.
Advances in Therapy|August 26, 2022
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect ComparisonNeal Shore, Shan Jiang, Viviana Garcia-Horton, et al.
European Urology Oncology|May 1, 2025
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE TrialsChristopher J D Wallis, Sara Ekberg, Alicia K Morgans, et al.
European Urology|August 31, 2014
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trialFred Saad, Johann de Bono, Neal Shore, et al.
The Journal of Urology|May 10, 2024
Reply by AuthorsYair Lotan, Siamak Daneshmand, Neal Shore, et al.
Future Oncology (London, England)|March 13, 2020
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBCAshish M Kamat, Neal Shore, Noah Hahn, et al.
Practical Radiation Oncology|September 1, 2023
Barrigel Spacer Injection TechniqueGlen Gejerman, Martin M Goldstein, Michael Chao, et al.
Pageof 20